Table 2. Association of PTMA immunostaining pattern with clinicopathological variables in the in-house cohort.
| Parameter | PTMA low | PTMA high | Fisher’s exact P-value | |
|---|---|---|---|---|
| Gender | Male | 37 | 26 | 0.412 |
| Female | 13 | 5 | ||
| Age | <45 | 30 | 14 | 0.252 |
| >45 | 20 | 17 | ||
| Grade | I | 5 | 0 | 0.018 |
| II | 26 | 9 | ||
| III | 10 | 9 | ||
| IV | 9 | 13 | ||
| p53 mutation | Absent | 38 | 18 | 0.137 |
| Present | 12 | 13 | ||
| IDH1 mutation | Absent | 28 | 22 | 0.241 |
| Present | 22 | 9 | ||
| ATRX mutation | Absent | 17 | 13 | 0.488 |
| Present | 33 | 18 | ||
| MIB-I index | Low (<10) | 39 | 13 | 0.002 |
| High (>10) | 11 | 18 | ||
Prognostic significance of PTMA in glioma. Abbreviation: ATRX, α-thalassemia/intellectual disability syndrome X-linked.